Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 5 ans
A double-blind, randomized, placebo-controlled, parallel, time-lagged, ascending, multi-centre, multiple-dose study to measure the magnitude and time course of the effect of FTY720 on FEV1 and other pulmonary function tests (FVC, FEF25-75%, and FEV1/FVC) in patients with moderate asthma
• To measure the magnitude and time course of the effect of FTY720 on FEV1 and other pulmonary function tests (FVC, FEF25-75%, and FEV1/FVC) in patients with moderate asthma. • To assess the safety an...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancer
The primary objective of the study is to evaluate the efficacy of Zometa in delaying disease progression, disease recurrence or death in patients with locally advanced, stage IIIA and IIIB NSCLC. The ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 5 ans
Study of safety and tolerability and preliminary efficacy of LNA043 in patients undergoing autologous chondrocyte implantation
• To assess the efficacy of a single LNA043 i.a. injection in regenerating hyaline cartilage tissue at the donor sites of patients undergoing autologous chondrocyte implantation (ACI) • To assess saf...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 6 ans
Étude CLDK378A2112 : étude de phase 1 visant à comparer l’exposition systémique, l’efficacité et la sécurité d’emploi du céritinib à 450 ou 600 mg avec un repas pauvre en gras à du céritinib à 750 mg à jeun chez des patients ayant un cancer de poumon non à petites cellules métastatique avec réarrangements d’ALK (positif pour ALK).
Le cancer du poumon non à petites cellules est le type de cancer du poumon le plus fréquent, qui représente 85-90% de l’ensemble des cancers du poumon. Les réarrangements du gène ALK sont présents da...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man
Max and 18 years
Novartis Pharma
Update Il y a 5 ans
Étude BIANCA : étude de phase 2 évaluant l’efficacité et la sécurité du tisagenlecleucel, chez des enfants ayant un lymphome non hodgkinien en rechute ou réfractaire.
Le lymphome est un cancer du système lymphatique qui se développe quand une erreur survient au niveau de la fabrication des lymphocytes, conduisant à la production de cellules anormales. Le système l...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapie Cellulaire
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
For Period II • To assess safety and tolerability of four doses of ACZ885 (5 mg, 15 mg, 50 mg, and 150 mg) vs. placebo as an add-on regimen over 4 months. • To assess the effect on HbA1c of four doses...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals
Update Il y a 5 ans
Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients
This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with mild Alzheimer's disease.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A multi-centre randomized double blind 12-week study to assess the efficacy, safety and tolerability of QVA149 in patients with COPD who have moderate to severe airflow limitation Multicentrična, randomizirana, dvojno slepa, 12-tedenska študija za oceno učinkovitosti, varnosti in prenosljivosti zdravila QVA149 pri bolnikih s KOPB z zmerno do zelo zmanjšanim pretokom zraka
To demonstrate the superiority of QVA149 27.5/12.5 μg b.i.d. compared to monotherapy components, QAB149 27.5 μg b.i.d. and NVA237 12.5 μg b.i.d., in terms of standardized FEV1AUC0-12 at Week 12.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 5 ans
NOVARTIS CHSP990A2101 : Essai de phase 1 évaluant le HSP990, chez des patients ayant une tumeur solide avancée. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase I dose escalation, multi-center, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.
Country
France
organs
Tumeurs solides
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Demonstrate the Effect of 12 Weeks Treatment with Initial Combination of Vildagliptin 100 mg qd plus Metformin 1000 mg bid as compared to Metformin 1000 mg bid in Drug-naïve Patients with Type 2 Diabetes
To demonstrate the efficacy of vildagliptin in drug naïve patients with type 2 diabetes by testing the hypothesis that the HbA1c reduction with initial combination of vildagliptin 100 mg qd plus metfo...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next